EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Progress of Clinical Studies Targeting Claudin18.2 for the Treatment of Gastric Cancer

Wu-Mei Jin, Yan Zhu, Zhi-Qiang Cai, Na He, Zhi-Qiong Yu, Shuang Li, Ji-Yuan Yang

Digestive Diseases and Sciences · 2024

DOI: 10.1007/s10620-024-08435-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Digestive Diseases and Sciences, 2024. Verfasst von Wu-Mei Jin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People's Republic of China. Hauptthemen laut MEDLINE: Claudins, Stomach Neoplasms, Molecular Targeted Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 108 Literaturangaben. Gefördert von: Jingzhou Science and Technology Program Guidance Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Claudin18.2 is a tight junction protein, highly selective, generally expressed only in normal gastric mucosal epithelial cells, which can effectively maintain the polarity of epithelial and endothelial cells, thus effectively regulating the permeability and conductance of the paracellular pathway. Abnormal expression of Claudin18.2 can occur in various primary malignant tumors, especially gastrointestinal tumors, and even in metastatic foci. It regulates its expression by activating the aPKC/MAPK/AP-1 pathway, and therefore, the Claudin18.2 protein is a pan-cancer target expressed in primary and metastatic lesions in human cancer types. Zolbetuximab (IMAB362), an antibody specific for Claudin18.2, has been successfully tested in a phase III clinical trial, and the results of the study showed that combining Zolbetuximab with chemotherapy notably extends patients' survival and is expected to be a potential first-line treatment for patients with Claudin18.2(+)/HER-2(-) gastric cancer. Here, we systematically describe the biological properties and oncogenic effects of Claudin18.2, centering on its clinical-pathological aspects and the progress of drug studies in gastric cancer, which can help to further explore its clinical value.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClaudinsStomach NeoplasmsMolecular Targeted TherapyAntineoplastic AgentsAntibodiesHumansAnimalsImmunotherapyClinical Trials as Topic

Stichwörter der Autor:innen

Claudin18.2Clinical trialDiagnosisMolecular biomarkerTargeted therapy

Substanzen

CLDN18 protein, humanClaudinsAntineoplastic AgentsAntibodies

Autor:innen und Institutionen

  • Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People's Republic of China.
  • Department of General, First Affiliated Hospital of Yangtze University, Jingzhou, People's Republic of China.
  • Department of Respiratory, First Affiliated Hospital of Yangtze University, Jingzhou, People's Republic of China.
  • Department of Oncology, First Affiliated Hospital of Yangtze University, Jingzhou, People's Republic of China. 2022721105@yangtzeu.edu.cn.

Förderung

  • Jingzhou Science and Technology Program Guidance Project

Zitieren

APA

Jin, W. M., Zhu, Y., Cai, Z. Q., He, N., Yu, Z. Q., Li, S., & Yang, J. Y. (2024). Progress of Clinical Studies Targeting Claudin18.2 for the Treatment of Gastric Cancer. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-024-08435-4

Vancouver

Jin WM, Zhu Y, Cai ZQ, He N, Yu ZQ, Li S, et al. Progress of Clinical Studies Targeting Claudin18.2 for the Treatment of Gastric Cancer. Digestive Diseases and Sciences. 2024. doi:10.1007/s10620-024-08435-4

BibTeX
@article{Jin2024,
  author = {Jin, Wu-Mei and Zhu, Yan and Cai, Zhi-Qiang and He, Na and Yu, Zhi-Qiong and Li, Shuang and Yang, Ji-Yuan},
  title = {Progress of Clinical Studies Targeting Claudin18.2 for the Treatment of Gastric Cancer},
  journal = {Digestive Diseases and Sciences},
  year = {2024},
  doi = {10.1007/s10620-024-08435-4}
}
Kostenlos starten →